Who
Lori A. Woods
Director
Company insider
Files Form 4 as: CEO, Perspective Therapeutics.
In numbers
- Trades disclosed
- 57
- Buys
- 14
- Sells
- 0
- Bought
- $424K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jun 2007
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 31 Mar 2025filed 1 Apr 2025 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K23,475 at $2.13 | filing |
| 3 Mar 2025filed 5 Mar 2025 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $49K4,504 at $10.90 | filing |
| 14 Jun 2024filed 18 Jun 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $89683 at $10.80 | filing |
| 3 Jun 2024filed 4 Jun 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K34,246 at $1.46 | filing |
| 15 Dec 2023filed 18 Dec 2023 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $41K152,962 at $0.27 | filing |
| 14 Dec 2023filed 18 Dec 2023 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,70432,238 at $0.27 | filing |
| 12 Dec 2023filed 14 Dec 2023 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 17 Apr 2023filed 19 Apr 2023 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,566 at $0.00 | filing |
| 17 Apr 2023filed 19 Apr 2023 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Code M | $14K23,566 at $0.61 | filing |
| 13 Apr 2023filed 19 Apr 2023 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —163,934 at $0.00 | filing |
| 13 Apr 2023filed 19 Apr 2023 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Code M | $100K163,934 at $0.61 | filing |
| 21 Feb 2023filed 23 Feb 2023 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —470,000 at $0.00 | filing |
| 21 Feb 2023filed 23 Feb 2023 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 15 Nov 2022filed 17 Nov 2022 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $34K100,000 at $0.34 | filing |
| 21 Jul 2022filed 28 Jul 2022 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —940,000 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $23K75,000 at $0.30 | filing |
News
FDA Grants Fast Track To Perspective Therapeutics' PSV359CATX · finanzen.ch · 8 Oct 2026Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical SymposiumCATX · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Lori A. Woods; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.